Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MERUS LABS INTERNATIONAL INC T.MSL

Healthcare Drug Manufacturers - Specialty & Generic
"Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products."


TSX:MSL - Post by User

MERUS LABS INTERNATIONAL INC > ebitda emphasis is sort changing the co.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2151)
•••
Comment by lscfaon Feb 28, 2017 3:44pm
166 Views
Post# 25907657

RE:ebitda emphasis is sort changing the co.

RE:ebitda emphasis is sort changing the co.Let's hope mgmt is not dumb enough to let a buyer price a takeover on EBITDA multiples.....
lscfa wrote: ebitda does not give co. credit for low interest rate and low tax rate so market is mis-valuing the stock.


Current adj ebitda $10.85 mil
Annualized = $43.4 mil
EV/ ebitda multiple of 6 => $260.4 mil
Less net debt of $136.5 mil => equity of $124 mil
117 mil shs. => $1.06
 
Current adj. eps = $0.062
Annualized = $0.248
p/e multiple of 8 => $1.98

net loss   -6,317,410
fx losses (gains) 3,748,357
amort of intangibles 8,941,592
legal settlement 998,176
acquisition costs 0
derivative losses (gains) -77,410
adj net income 7,293,305
shs avg o/s 116,999,906
adj eps   $0.062




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities